The Macropinocytosis Company
Tezcat Biosciences is an early-stage biopharmaceutical company that develops receptor-independent drug delivery technology for the most aggressive cancers. Born out of NYU Langone Health, its proprietary macropinocytosis platform delivers therapeutic payloads specifically to RAS-mutant tumor cells. Its lead asset TZT-102 targets relapsed/refractory multiple myeloma and is supported by NCI SBIR Phase II funding.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2025
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
